3 Jun 2025 Date | | - Cons. EPS | - EPS |
18 Dec 2024 Date | | - Cons. EPS | - EPS |
21 Aug 2024 Date | | - Cons. EPS | - EPS |
5 Jun 2024 Date | | - Cons. EPS | - EPS |
16 May 2024 Date | | - Cons. EPS | - EPS |
3 Jun 2025 Date | | - Cons. EPS | - EPS |
18 Dec 2024 Date | | - Cons. EPS | - EPS |
21 Aug 2024 Date | | - Cons. EPS | - EPS |
5 Jun 2024 Date | | - Cons. EPS | - EPS |
16 May 2024 Date | | - Cons. EPS | - EPS |
Drug Manufacturers - Specialty & Generic Industry | Healthcare Sector | Mr. Markwin M. Maring CEO | OTC PINK Exchange | 13767L109 Cusip |
US Country | 4 Employees | - Last Dividend | 23 Jan 2020 Last Split | - IPO Date |
Cannonau Corp. emerged onto the market scene with a focus on providing products based on cannabidiol (CBD), marking a shift in its business direction from its previous identity as Pacific Blue Energy Corp. This transformative rebranding took place in August 2019, reflecting the company's new strategic focus on capitalizing on the burgeoning CBD market. Established in 2007 and headquartered in Skaneateles, New York, Cannonau Corp. has positioned itself within the growing wellness and health sector, offering innovative CBD-based solutions to meet the evolving needs and preferences of consumers.